IgG ANTIBODY RESPONSE BY ELISA USING WUHAN AND LAMBDA VARIANT ANTIGENS IN BBIBP-CORV VACCINATED HEALTH CARE WORKERS

García-Mendoza M.; Merino-Sarmiento N.; De Lucio-Burga G.; Fernández-Navarro M.G.; Pampa-Espinoza L.; Solis-Sánchez G.; Huaringa-Núñez M.; Palomino-Rodríguez M.; Ríos-Monteza P.; Solari L. · Revista Peruana de Medicina Experimental y Salud Publica (2022) · DOI: 10.17843/rpmesp.2022.393.10875

Resumen

Objectives. To evaluate the IgG antibody response by ELISA using Wuhan and Lambda antigens in health care workers with and without history of SARS-CoV-2 infection prior to immunization with the first and second doses of Sinopharm vaccine (BBIBP-CorV). Materials and methods. An analytical study was carried out in health care workers over 18 years of age. Fifty-one participants with history and 100 participants without history of SARS-CoV-2 infection, who received two doses of Sinopharm vaccine, were included. IgG antibodies were assessed 21 days after the first dose, 21 days after the second dose and 3 months after the second dose by in-hou-se ELISA using the complete antigen of the Wuhan variant (B.1.1) and lambda variant (C-37) of SARS-CoV-2 virus. Results. Both groups showed a large increase in the percentage of people with antibodies after the second dose, however, this percentage decreased 3 months after the second dose. The difference between the antibody index measured by ELISA with Wuhan variant antigen versus the ELISA with lambda variant was significant (p<0.001). Conclusions. There is a significant increase in the presence of IgG type antibodies after 15 days of the second dose of BBIBP-CorV vaccination in participants without previous infection and a decrease after 3 months of the second dose in the ratio of IgG antibody reactivity indexes in ELISAs with the variant antigen as with ELISAs with the lambda variant.